title: Bexarotene and systemic disease progression in CTCL?
authors.forename: Reinhard
authors.initials: R
authors.lastname: Dummer
authors.forename: Axel
authors.initials: A
authors.lastname: Hauschild
authors.forename: Jeannine
authors.initials: J
authors.lastname: Skalsky
authors.forename: Günter
authors.initials: G
authors.lastname: Burg
authors.forename: Michael
authors.initials: M
authors.lastname: Weichenthal
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000077610:Bexarotene; D018450:Disease Progression; D006801:Humans; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy*; D009182:Mycosis Fungoides / Q000188:drug therapy; D015203:Reproducibility of Results; D012307:Risk Factors; D012751:Sezary Syndrome / Q000188:drug therapy; D013764:Tetrahydronaphthalenes / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D013764:Tetrahydronaphthalenes; D000077610:Bexarotene